Wedbush Upgrades Unum Therapeutics (UMRX) to Outperform
Tweet Send to a Friend
Wedbush analyst David Nierengarten upgraded Unum Therapeutics (NASDAQ: UMRX) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE